1-20 of 34
Emmanuelle di Tomaso
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2663: Preclinical profiling of BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy

Silvia Goldoni, Martin Lange, Charlotte Kopitz, Stefan Kaulfuss, Sven Golfier, Adrian Tersteegen, Stefanie Bunse, Melanie Berthold, Thibaud Jordan, Philip Lienau, Franziska Siegel, Annette Walter, Henrik Seidel, Elisa Aquilanti, Andrew Baker, Xiaoyun Wu, Sooncheol Lee, Stefan Gradl, Emmanuelle di Tomaso, Matthew Meyerson, Knut Eis, Ashley Eheim, Heidi Greulich
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2663.
https://doi.org/10.1158/1538-7445.AM2022-2663
Published: 15 June 2022
View article titled, Abstract 2663: Preclinical profiling of BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy
Journal Articles

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7

Shanhu Hu, Jason J. Marineau, Nisha Rajagopal, Kristin B. Hamman, Yoon Jong Choi, Darby R. Schmidt, Nan Ke, Liv Johannessen, Michael J. Bradley, David A. Orlando, Sydney R. Alnemy, Yixuan Ren, Stephane Ciblat, Dana K. Winter, Anzhelika Kabro, Kevin T. Sprott, J. Graeme Hodgson, Christian C. Fritz, John P. Carulli, Emmanuelle di Tomaso, Eric R. Olson
Journal: Cancer Research
Cancer Res (2019) 79 (13): 3479–3491.
https://doi.org/10.1158/0008-5472.CAN-19-0119
Published: 01 July 2019
View article titled, Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7
Open the PDF for Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7 in another window
Includes: Supplementary data
Journal Articles

Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo

Panagiotis A. Konstantinopoulos, Graeme Hodgson, Nisha Rajagopal, Liv Johannessen, Joyce F. Liu, Paul T. Kirschmeier, Shan Zhou, Cam Anh Tran, David Orlando, Christian Fritz, Emmanuelle di Tomaso, Ursula A. Matulonis
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1525.
https://doi.org/10.1158/1538-7445.AM2018-1525
Published: 01 July 2018
View article titled, Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo
Journal Articles

Abstract 3596: Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX)

Marta Palafox, María Teresa Herrera-Abreu, Meritxell Bellet, Mafalda Oliveira, Alejandra Bruna, Olga Rodriguez, Marta Guzmán, Judit Grueso, Cristina Vilaplana, Joaquín Arribas, Emmanuelle di Tomaso, Faye Su, Carlos Caldas, Nicholas C. Turner, Rodrigo Dienstmann, José Baselga, Maurizio Scaltriti, Javier Cortés, Cristina Saura, Violeta Serra
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3596.
https://doi.org/10.1158/1538-7445.AM2018-3596
Published: 01 July 2018
View article titled, Abstract 3596: Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX)
Journal Articles

Abstract 2825: Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX)

Violeta Serra, Marta Palafox, Maria-Teresa Herrera, Martin A Rivas, Marta Guzmán, Olga Rodriguez, Judit Grueso, Meritxell Bellet, Mafalda Oliveira, Cristina Saura, Emmanuelle di Tomaso, Giordi Camponigro, Nicholas C. Turner, Javier Cortés, José Baselga
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2825.
https://doi.org/10.1158/1538-7445.AM2016-2825
Published: 15 July 2016
View article titled, Abstract 2825: Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX)
Journal Articles

Abstract 4698: Combination of ceritinib (LDK378) with PI3K inhibitors (buparlisib [BKM120] and alpelisib [BYL719]) demonstrates synergistic preclinical antitumor activity in ALK-rearranged non-small cell lung cancer (NSCLC)

Emmanuelle Di Tomaso, Ronald Linnartz, Fang Li, Cristian Massacesi, Samit Hirawat
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4698.
https://doi.org/10.1158/1538-7445.AM2015-4698
Published: 01 August 2015
View article titled, Abstract 4698: Combination of ceritinib (LDK378) with PI3K inhibitors (buparlisib [BKM120] and alpelisib [BYL719]) demonstrates synergistic preclinical antitumor activity in ALK-rearranged non-small cell lung cancer (NSCLC)
Journal Articles

Abstract P5-05-04: Acquired resistance to everolimus occurs independently of mTORC1 inhibition in preclinical in vivo models of ER+ breast cancer

Neil A O'Brien, Dylan Conklin, Michaela Ching, Luo Tong, Raul Ayala, Shawnt Issakhanian, Sara A Hurvitz, Emmanuelle di Tomaso, Ronald Linnartz, Richard S Finn, Samit Hirawat, Dennis J Slamon
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-05-04.
https://doi.org/10.1158/1538-7445.SABCS14-P5-05-04
Published: 01 May 2015
View article titled, Abstract P5-05-04: Acquired resistance to everolimus occurs independently of mTORC1 inhibition in preclinical in vivo models of ER+ breast cancer
Journal Articles

A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition

Hailing Cheng, Pixu Liu, Fan Zhang, Erbo Xu, Lynn Symonds, Carolynn E. Ohlson, Roderick T. Bronson, Sauveur-Michel Maira, Emmanuelle Di Tomaso, Jane Li, Andrea P. Myers, Lewis C. Cantley, Gordon B. Mills, Jean J. Zhao
Journal: Cancer Research
Series: Author Choice
Cancer Res (2014) 74 (1): 15–23.
https://doi.org/10.1158/0008-5472.CAN-13-0544
Published: 05 January 2014
View article titled, A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition
Open the PDF for A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition in another window
Includes: Supplementary data
Journal Articles

Abstract 2713: The Pten and p53 tumor suppressors cooperate to constrain the PI3K/mTOR pathway activation.

Pixu Liu, Hailing Cheng, Lynn Symonds, Erbo Xu, Sauveur-Michel Maira, Emmanuelle di Tomaso, Thomas Roberts, Jean Zhao
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2713.
https://doi.org/10.1158/1538-7445.AM2013-2713
Published: 15 April 2013
View article titled, Abstract 2713: The Pten and p53 tumor suppressors cooperate to constrain the PI3K/mTOR pathway activation.
Journal Articles

Abstract 579: Cell death induction end-points to identify new cancer indications with high likelihood of response to dual PI3K /mTOR inhibitors

Alan Huang, Joseph Lehar, Elina Pradhan, Emmanuelle Di Tomaso, Maria Villarroel, Wolfgang Hackl, Cornelia Quadt, Christine Fritsch, Andreas Weiss, Saskia Brachmann, Robert Schlegel, Francesco Hofmann, Michel Maira
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 579.
https://doi.org/10.1158/1538-7445.AM2011-579
Published: 15 April 2011
View article titled, Abstract 579: Cell death induction end-points to identify new cancer indications with high likelihood of response to dual PI3K /mTOR inhibitors
Journal Articles

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape

Emmanuelle di Tomaso, Matija Snuderl, Walid S. Kamoun, Dan G. Duda, Pavan K. Auluck, Ladan Fazlollahi, Ovidiu C. Andronesi, Matthew P. Frosch, Patrick Y. Wen, Scott R. Plotkin, E. Tessa Hedley-Whyte, A. Gregory Sorensen, Tracy T. Batchelor, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2011) 71 (1): 19–28.
https://doi.org/10.1158/0008-5472.CAN-10-2602
Published: 02 January 2011
View article titled, Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape
Open the PDF for Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape in another window
Includes: Supplementary data
Journal Articles

Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors

Hon Kit Wong, Johanna Lahdenranta, Walid S. Kamoun, Annie W. Chan, Andrea I. McClatchey, Scott R. Plotkin, Rakesh K. Jain, Emmanuelle di Tomaso
Journal: Cancer Research
Cancer Res (2010) 70 (9): 3483–3493.
https://doi.org/10.1158/0008-5472.CAN-09-3107
Published: 28 April 2010
View article titled, Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors
Open the PDF for Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract LB-213: Plasma soluble VEGFR1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

Dan G. Duda, Christopher G. Willett, Marek Ancukiewicz, Emmanuelle di Tomaso, Mira Shah, Brian G. Czito, Rex Bentley, Martin Poleski, Gregory Y. Lauwers, Madeline Carroll, Douglas Tyler, Christopher Mantyh, Paul Shellito, Jeffrey W. Clark, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): LB-213.
https://doi.org/10.1158/1538-7445.AM10-LB-213
Published: 15 April 2010
View article titled, Abstract LB-213: Plasma soluble VEGFR1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer
Journal Articles

Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer

Lei Xu, Dan G. Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Daniel C. Chung, Gregory Y. Lauwers, Rekha Samuel, Paul Shellito, Brian G. Czito, Pei-Chun Lin, Martin Poleski, Rex Bentley, Jeffrey W. Clark, Christopher G. Willett, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2009) 69 (20): 7905–7910.
https://doi.org/10.1158/0008-5472.CAN-09-2099
Published: 14 October 2009
View article titled, Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer
Open the PDF for Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer in another window
Journal Articles

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

A. Gregory Sorensen, Tracy T. Batchelor, Wei-Ting Zhang, Poe-Jou Chen, Priscilla Yeo, Meiyun Wang, Dominique Jennings, Patrick Y. Wen, Johanna Lahdenranta, Marek Ancukiewicz, Emmanuelle di Tomaso, Dan G. Duda, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2009) 69 (13): 5296–5300.
https://doi.org/10.1158/0008-5472.CAN-09-0814
Published: 01 July 2009
View article titled, A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
Open the PDF for A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract #LB-94: A \#8220;vascular normalization index\#8221; as a mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients: Insights from a Phase II study

A. Gregory Sorensen, Tracy Batchelor, Marek Ancukiewicz, Wei-Ting Zhang, Poe-Jou Chen, Priscilla Yeo, Meiyun Wang, Dominique Jennings, Patrick Wen, Johanna Lahdenranta, Emmanuelle di Tomaso, Dan Duda, Rakesh Jain
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): LB-94.
Published: 01 May 2009
View article titled, Abstract #LB-94: A \#8220;vascular normalization index\#8221; as a mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients: Insights from a Phase II study
Journal Articles

Abstract #4070: Inhibition of the VEGF pathway can alleviate growth of NF2-associated schwannomas

Hon-Kit Andus Wong, Johanna Lahdenranta, Annie Chan, Scott Plotkin, Andrea McClatchy, Rakesh Jain, Emmanuelle Di Tomaso
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4070.
Published: 01 May 2009
View article titled, Abstract #4070: Inhibition of the VEGF pathway can alleviate growth of NF2-associated schwannomas
Journal Articles

Abstract #2005: PDGF-CC normalizes vessels in glioblastoma xenorafts.

Emmanuelle Di Tomaso, Nyall London, Daniel Fuja, James Logie, Lance Munn, Rakesh Jain
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2005.
Published: 01 May 2009
View article titled, Abstract #2005: PDGF-CC normalizes vessels in glioblastoma xenorafts.
Journal Articles

Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Tracy T Batchelor, Gregory Sorensen, Emmanuelle di Tomaso, Dan G Duda, Wei-Ting Zhang, Marek Ancukiewicz, Johanna Lahdenranta, David Louis, Scott Plotkin, Percy Ivy, Jay S Loeffler, Patrick Wen, Rakesh K Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-247.
https://doi.org/10.1158/1538-7445.AM2008-LB-247
Published: 15 May 2008
View article titled, Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Journal Articles

Abstract LB-304: Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer

Christopher G Willett, Lei Xu, Dan G Duda, Emmanuelle di Tomaso, Yves Boucher, Johanna Lahdenranta, Marek Ancukiewicz, Johanna Bendell, Brian Czito, Lawrence Blaszkowsky, Jeffrey Clark, Rakesh K Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-304.
https://doi.org/10.1158/1538-7445.AM2008-LB-304
Published: 15 May 2008
View article titled, Abstract LB-304: Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer